
baybiosciences.com
Mar 18, 2025, 12:43
Oliver Maracic: Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer LGSOC
Oliver Maracic, Investor, shared a post on LinkedIn:
“Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer LGSOC (ENGOT-ov60/GOG-3052/RAMP 201): Dose Intensity and Subgroup Analysis
In KRASm patients,
– ORR was 47% (no prior MEK inhibitor, n=45) vs 33% (prior MEK inhibitor, n=12),
– 53% (no prior bevacizumab, n=34) vs 30% (prior bevacizumab, n=23),
– 49% (1-3 prior therapies, n=35) vs 36% (>3 prior therapies, n=22).
In KRAS wild-type patients,
– ORR was 18% (no prior MEK inhibitor, n=39) vs 15% (prior MEK inhibitor, n=13),
– 25% (no prior bevacizumab, n=20) vs 13% (prior bevacizumab, n=32),
– 21% (1-3 prior therapies, n=28) vs 13% (>3 prior therapies, n=24).”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 18, 2025, 16:54
Mar 18, 2025, 16:25
Mar 18, 2025, 16:07
Mar 18, 2025, 14:56
Mar 18, 2025, 14:40
Mar 18, 2025, 13:16